Korea Technology Finance Corporation ( Korea Technology Finance Corporation, Chairman Kim Jong-ho , hereinafter referred to as “ KIBO ”) is a non-profit organization established by Innoboterapeutics Co., Ltd. , Curogen Co., Ltd. , Kimcell & Gene Co., Ltd. , Four bio venture companies, including Proen Therapeutics, were selected as 'IP-Value Powerhouses ' and each company was given a grant of 1 billion won based on the value assessment results of the new drug candidates owned by each company. On Friday the 30th , it was announced that it supported the ' Excellent IP Value Plus Guarantee ' ( hereinafter referred to as ' Value Plus Guarantee ') .
The Value Plus Guarantee is a guarantee provided by the Korea Institute of Technology Evaluation and Planning in cooperation with universities , public research institutes , and partner organizations. Discover high value-added, advanced technology-based intellectual property (IP) and derive value based on technology valuation This is a customized guarantee product that supports commercialization funding within the value amount . Kibo awards IP-Value Strong Small and Medium Enterprise Certificates to companies selected for excellent IP through high-difficulty technology valuation .
The four companies selected this time are promising bio companies jointly discovered by Kibo and the National Drug Development Foundation ( Director Park Young-min , hereinafter referred to as the " Foundation ") through a National Drug Development Project agreement project. The selection ceremony was held at the Foundation headquarters in Mapo-gu, Seoul, attended by Kibo Director Lee Jae-pil , Foundation Director Park Young-min , and the selected companies . It was held with representatives and others in attendance .
Inovo Therapeutics Co., Ltd. ( CEO Hee-Dong Park ) is a company established in 2019 that develops oral synthetic drug-based A treatment for ulcerative colitis is being developed . The substance inhibits the regeneration-inhibiting enzyme 15-PGDH . It inhibits tissue regeneration by increasing the physiological concentration of prostaglandin E2 (PGE2) in the intestinal mucosa. It is a method of induction , and is currently completing preclinical trials and preparing for approval of the clinical trial plan (IND) .
Kyrogen Co., Ltd. ( CEO Chang-Woo Lee ) is a company established in 2019 that regulates inflammation and autoimmune responses . We are developing an innovative new drug that selectively inhibits the core mechanism , and it is currently in the preclinical stage .
Founded in 2020 , Kimcell & Gene Co., Ltd. ( CEO: Hyo-soo Kim ) possesses a monoclonal antibody-based new drug candidate that blocks signaling through the CAP1 receptor of the inflammation-inducing resistin . The drug targets the treatment of inflammatory bowel disease and is nearing preclinical trials .
Proen Therapeutics Co., Ltd. ( CEO Il-Han Lee ) is a company established in 2015 that develops epidermal growth factor receptor (EGFR) We are developing a targeted antibody-drug conjugate (ADC) -based treatment for advanced metastatic colorectal cancer . Our core technology, "ArtBody," has the potential to expand beyond ADCs to theranostics , a technology that simultaneously performs diagnosis and treatment .
In addition to this guarantee support, Kibo will actively support the commercialization of excellent technologies through various preferential benefits such as ▲reduction of guarantee fees ▲free support for pre-diagnosis evaluation for technology special listing ▲technology evaluation certification for investment purposes. It's a plan .
Lee Jae-pil, CEO of Kibo, said , “ New drug development has a long recovery period and high risk, so existing financial methods have limitations in providing support ,” and added , “ Kibo will continue to actively discover excellent bio venture companies through cooperation with relevant organizations and spare no support so that their technologies can lead to successful commercialization.” He said, "I will not do it . "
- See more related articles
You must be logged in to post a comment.